The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As employers grapple with soaring healthcare costs, telehealth provider Hims & Hers Health is poised to benefit from a potential shift away from expensive branded weight-loss drugs. The company may get a boost next year from employers dropping coverage of Novo Nordisk's Wegovy and Eli Lilly's Zepbound to rein in costs, analysts and investors say.
The trend reflects a broader cost-cutting push in the U.S. healthcare system, with employers increasingly seeking cheaper alternatives to manage employee wellness. Hims, which offers compounded versions of weight-loss medications at lower prices, could see increased demand as branded coverage declines. Analysts highlight that the company's direct-to-consumer model and competitive pricing make it an attractive option for cost-conscious employers.
Sign in to access this content
Sign InLooking ahead, investors will watch for Hims' upcoming quarterly results and any announcements of new employer partnerships. The company's ability to scale production and maintain pricing will be key. Additionally, any regulatory changes affecting compounded drugs could influence the stock's trajectory.